Chatterjee, S; Moeller, C; Shah, N; Bolorunduro, O; Lichstein, E; Moskovits, N; Mukherjee, D (August 2012). “Eplerenone is not superior to older and less expensive aldosterone antagonists.”. The American Journal of Medicine125 (8): 817–25. doi:10.1016/j.amjmed.2011.12.018. PMID22840667.
Delyani, John A (2000). “Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology”. Kidney International57 (4): 1408–1411. doi:10.1046/j.1523-1755.2000.00983.x. ISSN0085-2538.
Struthers, Allan; Krum, Henry; Williams, Gordon H. (April 2008). “A Comparison of the Aldosterone-blocking Agents Eplerenone and Spironolactone”. Clinical Cardiology31 (4): 153–158. doi:10.1002/clc.20324.
Struthers A, Krum H, Williams GH (2008). “A comparison of the aldosterone-blocking agents eplerenone and spironolactone”. Clin Cardiol31 (4): 153–8. doi:10.1002/clc.20324. PMID18404673.
Chatterjee, S; Moeller, C; Shah, N; Bolorunduro, O; Lichstein, E; Moskovits, N; Mukherjee, D (August 2012). “Eplerenone is not superior to older and less expensive aldosterone antagonists.”. The American Journal of Medicine125 (8): 817–25. doi:10.1016/j.amjmed.2011.12.018. PMID22840667.
Struthers A, Krum H, Williams GH (2008). “A comparison of the aldosterone-blocking agents eplerenone and spironolactone”. Clin Cardiol31 (4): 153–8. doi:10.1002/clc.20324. PMID18404673.
Delyani, John A (2000). “Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology”. Kidney International57 (4): 1408–1411. doi:10.1046/j.1523-1755.2000.00983.x. ISSN0085-2538.